We hereby Submitted the Financial Result for the Financial Year ended 31 March 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
iSERA Lifesciences (formerly Covidh Technologies) reported strong top-line growth with revenue from operations surging to ₹135.50 Lakhs from ₹26.52 Lakhs in the prior year—a 5x increase. PAT grew to ₹25.94 Lakhs from ₹11.81 Lakhs (+120%). The company completed a rights issue allotting 80,85,550 equity shares at ₹10 each, raising ₹808.55 Lakhs, which expanded share capital significantly. Despite profit growth, operating cash flow turned sharply negative at ₹-535.42 Lakhs due to large increases in other financial assets (₹501.94 Lakhs) and trade receivables (₹88.87 Lakhs). Operating profit margin compressed from ~52% to ~25%. Auditors GMKS & Co issued an unmodified opinion with no going concern or qualification issues.
Revenue and PAT growth are impressive, but the massive equity dilution from the rights issue significantly reduced EPS (₹0.74 vs ₹3.65) and the negative operating cash flow raises working capital concerns despite the clean audit opinion.